Iovance Biotherapeutics has expanded its relationship with WuXi AppTec's Advanced Therapies Business Unit (WuXi ATU). WuXi will increase capacity for Iovance's innovaTIL-01 and innovaTIL-04 studies, which offer lifileucel and LN-145 for treatment of metastatic melanoma and recurrent, metastatic, or persistent cervical cancer, respectively.
"We are excited to continue our partnership with WuXi," said Maria Fardis, Ph.D., MBA, President and Chief Executive Officer of Iovance. "Being able to expand our relationship in order to broaden patient access to our treatments is very important to us. WuXi has been a strong partner in developing the Iovance TIL product and we look forward to further expansion of our ongoing relationship."
"We are pleased to expand our relationship and manufacturing partnership with Iovance, and look forward to helping to accelerate and expand their clinical trials where possible, so more patients get access to their treatments and the benefits they provide," Felix Hsu, SVP and Global Head of WuXi Advanced Therapies, said.
WuXi manufactures TIL products for Iovance at its Commerce Center 3 facility, a 55,000-square-foot late phase and commercial manufacturing facility for cell therapies. It is one of three facilities in the Philadelphia Navy Yard supporting the development, manufacturing and quality control testing of cell and gene therapies.